Icatibant Sun (Icatibant)

• Icatibant is a bradykinin B2 receptor antagonist used in the management of hereditary angioedema.
• Hereditary angioedema (HAE) acute attacks: rapid reduction of swelling and associated pain in adult patients.

• Icatibant selectively and competitively binds to the bradykinin B2 receptor on vascular endothelial cells, preventing bradykinin from activating the receptor. By blocking this pathway, it inhibits bradykinin‑induced vasodilation, increased vascular permeability, and subsequent plasma extravasation that cause the characteristic swelling of hereditary angioedema. The antagonism is rapid, allowing prompt reversal of acute edema episodes in patients and improves quality of life.

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the injection site.
• Injection site erythema: redness around the injection area.
• Injection site swelling: localized edema.
• Nausea: occasional feeling of queasiness.
• Headache: transient head pain.
• Dizziness: light‑headed sensation.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Severe hypotension: marked drop in blood pressure.
• Angioedema of the face or throat: swelling that may compromise airway.
• Urticaria: widespread hives.
• Thrombocytopenia: low platelet count.
• Severe injection site reaction: necrosis or extensive tissue damage.

Before using Icatibant, consider the following precautions to ensure safe administration.

• Hypersensitivity assessment: verify no known allergy to icatibant or any formulation components.
• Cardiovascular monitoring: observe patients with existing heart disease for blood pressure changes.
• Pregnancy and lactation: safety has not been established; use only if the potential benefit justifies the risk.
• Concomitant bradykinin‑modulating drugs: avoid combining with other B2 receptor antagonists.
• Renal or hepatic impairment: dose adjustment is not established; monitor clinical response.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• ACE inhibitors: may increase bradykinin levels and reduce icatibant efficacy.
• Neprilysin inhibitors (e.g., sacubitril): elevate bradykinin, potentially diminishing therapeutic effect.
• Estrogen‑containing therapies: can exacerbate hereditary angioedema severity.
• Other bradykinin B2 receptor antagonists: additive antagonism may lead to unexpected effects.
• Immunosuppressants that alter immune response: may affect injection site reactions.

Moderate Interactions (Monitor Closely)

• NSAIDs: may increase risk of gastrointestinal discomfort.
• Diuretics: monitor blood pressure and electrolyte balance.
• Corticosteroids: observe for enhanced immunosuppression.
• Antihistamines: may mask early signs of allergic reactions.
• Anticoagulants: watch for bleeding at injection sites.